CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Handheld Radiofrequency Spectroscopy for Intraoperative Assessment of Surgical Margins during Breast-Conserving Surgery

This policy governs coverage and medical necessity determinations for handheld radiofrequency spectroscopy devices (eg, MarginProbe) used intraoperatively to assess lumpectomy margins during breast-conserving surgery for Blue Cross Blue Shield - Rhode Island members.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyHandheld Radiofrequency Spectroscopy for Intraoperative Assessment of Surgical Margins during Breast-Conserving Surgery

Policy CodePolicy N/A

Change TypeNo material change

Effective DateJul 1, 2023

Next Review DateN/A

Key ActionDo not bill for handheld radiofrequency spectroscopy (eg, MarginProbe) for intraoperative margin assessment as it is not covered / not medically necessary.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Not coveredCoverage stance

0546TNot-covered code

Randomized + observational + SREvidence reviewed

~85%Device specificity

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Not Medically Necessary / Not Covered

Policy stance

Not covered / Not medically necessary: Handheld radiofrequency spectroscopy for intraoperative assessment of surgical margins during breast-conserving surgery (eg, MarginProbe) is not covered as the evidence is insufficient to demonstrate improvement in net health outcome.

Applies to Commercial Products and Medicare Advantage Plans as stated in the policy.

Use of the device is restricted to the excised primary lumpectomy specimen only. The MarginProbe (handheld radiofrequency spectroscopy) is applied to the surface of the main lumpectomy specimen to assess margins and provides positive/negative readings for each touch. It cannot be used on shavings taken from the specimen nor may it be used directly in the lumpectomy cavity within the patient’s breast; the policy’s coverage determination applies only to the intraoperative use described.

Handheld radiofrequency spectroscopy for intraoperative assessment of surgical margins during breast-conserving surgery (eg, MarginProbe) is not medically necessary / not covered. The evidence, including a randomized trial, observational studies, and systematic review, is insufficient to demonstrate improved net health outcomes. Limitations cited include trial design issues, moderate sensitivity with poor specificity, and lack of recurrence outcome data.

What Providers Need to Know

Prior Authorization

Prior authorization: Not applicable. Benefits may vary by contract and are subject to member-specific coverage documents.

Documentation Required

Benefit Verification

Provider action: Verify member benefits and coverage terms before providing services. Refer to the member's Benefit Booklet / Evidence of Coverage or Subscriber Agreement for contract-specific determinations of medical necessity and coverage exclusions.

Denial Risk

Coverage Denial Risk

Coverage/Denial Risk: Handheld radiofrequency spectroscopy (for example, MarginProbe) for intraoperative assessment of surgical margins during breast-conserving surgery is not covered / not medically necessary. Claims may be denied.

Not covered / not medically necessary for Commercial Products and Medicare Advantage Plans
Providers should expect claim denial when billed for handheld radiofrequency spectroscopy devices or related procedure codes

Clinical Background

Breast-conserving surgery (lumpectomy) aims to achieve tumor-free margins to avoid the need for re-excision; definitive determination of margin status currently relies on histologic examination of excised tissues. The MarginProbe is a handheld radiofrequency spectroscopy device that measures the dielectric properties of tissue where it contacts the lumpectomy specimen and gives a positive or negative touch reading to indicate tissue likely to be malignant or benign. It is intended to be applied to the excised specimen intraoperatively to help identify positive margins and thereby reduce re-excision, but published evidence shows moderate sensitivity, poor specificity, and methodologic limitations in trials and observational studies. Because of these limitations and the absence of demonstrated improvement in recurrence or other net health outcomes, available data do not support its routine use.

Definitions

Handheld radiofrequency spectroscopy (MarginProbe) — device definition

Device typeHandheld radiofrequency spectroscopy device (MarginProbe).

MeasurementMeasures dielectric properties of excised breast tissue where the probe contacts the specimen to distinguish malignant from benign tissue.

Output/readingsProvides positive or negative touch readings; any positive touch on a margin is considered a positive margin.

Application siteApplied to the main lumpectomy specimen only — not for use on shavings or within the lumpectomy cavity.

Intended useIntraoperative assessment of surgical margins during breast-conserving surgery to help identify margins that may require re-excision.